{
    "clinical_study": {
        "@rank": "35001", 
        "arm_group": {
            "arm_group_label": "AMG 232", 
            "arm_group_type": "Experimental", 
            "description": "AMG 232 is an anti-cancer agent."
        }, 
        "brief_summary": {
            "textblock": "First in human, open-label, sequential dose escalation and expansion study of AMG 232 in\n      subjects with advanced solid tumors."
        }, 
        "brief_title": "A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Malignancy", 
            "Advanced Solid Tumors", 
            "Cancer", 
            "Oncology", 
            "Oncology Patients", 
            "Tumors", 
            "GBM"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women > 18 years old\n\n          -  Pathologically documented, definitively diagnosed, advanced solid tumor that is\n             refractory to standard treatment, or which no standard therapy is available, or the\n             subject refuses standard therapy\n\n          -  Willing to undergo pre-dose core needle tumor biopsies\n\n          -  Ability to take oral medications and willing to record daily adherance to\n             investigational product\n\n          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments\n\n        Exclusion Criteria:\n\n          -  Active brain metastases\n\n          -  Prior bone marrow transplant\n\n          -  History or presence of hematological malignancies\n\n          -  Active infection requiring intravenous (IV) antibiotics\n\n          -  Anti-tumor therapy\n\n          -  Therapeutic or palliative radiation therapy\n\n          -  Currently enrolled in another investigational device or drug study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "107", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723020", 
            "org_study_id": "20120106"
        }, 
        "intervention": {
            "arm_group_label": "AMG 232", 
            "description": "Given an an oral tablet in escalating doses.", 
            "intervention_name": "AMG 232", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Solid Tumors", 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90403"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwalk", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06856"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Greenville Hospital System"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon CEDEX 08", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 CE"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "France: French National Agency of Medicine and Health Products Safety, ANSM"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1", 
            "measure": "Objective Tumor Response", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}